ATXS — Astria Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $494.22m
- $343.01m
- 36
- 19
- 81
- 42
Annual cashflow statement for Astria Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.3 | -37.3 | -195 | -51.8 | -72.9 |
| Depreciation | |||||
| Non-Cash Items | 1.57 | 1.45 | 168 | 5.65 | 6.86 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.87 | 3.37 | -3.31 | 2.65 | -2.41 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -26.6 | -32.5 | -30.2 | -43.5 | -68.4 |
| Capital Expenditures | -0.012 | -0.033 | -0.021 | -0.091 | -0.025 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -4.07 | 6.33 | -12.5 | -167 | 135 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -4.08 | 6.3 | -12.6 | -167 | 135 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 25.6 | 40.9 | 104 | 145 | 88.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -5.03 | 14.7 | 61.6 | -65.9 | 155 |